QCG
LKFT

Quadrant Capital Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Quadrant Capital Group’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$110K Buy
3,653
+133
+4% +$4.4K ﹤0.01% 1458
2025
Q4 		$115K Sell
3,520
-360
-9% -$11.6K ﹤0.01% 1463
2025
Q3 		$134K Buy
+3,880
New +$124K ﹤0.01% 1399
2025
Q2 		– Sell
-4,429
Closed -$111K – 1846
2025
Q1 		$111K Sell
4,429
-5,311
-55% -$134K ﹤0.01% 1505
2024
Q4 		$268K Sell
9,740
-1,528
-14% -$42.6K 0.02% 536
2024
Q3 		$324K Buy
11,268
+4,719
+72% +$129K 0.02% 477
2024
Q2 		$162K Buy
6,549
+4,715
+257% +$134K 0.01% 752
2024
Q1 		$59.1K Buy
1,834
+128
+8% +$4.76K ﹤0.01% 1300
2023
Q4 		$69.3K Buy
1,706
+261
+18% +$9.61K 0.01% 1203
2023
Q3 		$49.9K Buy
1,445
+50
+4% +$1.95K 0.01% 1263
2023
Q2 		$56.7K Buy
1,395
+1,228
+735% +$50.1K 0.01% 1192
2023
Q1 		$6.45K Buy
167
+153
+1,093% +$6.29K ﹤0.01% 2177
2022
Q4 		$621 Sell
14
-354
-96% -$14.9K ﹤0.01% 2597
2022
Q3 		$16K Sell
368
-203
-36% -$10.4K ﹤0.01% 1654
2022
Q2 		$32K Buy
571
+136
+31% +$8.06K ﹤0.01% 1064
2022
Q1 		$27K Buy
435
+52
+14% +$3.18K ﹤0.01% 1181
2021
Q4 		$21K Buy
383
+188
+96% +$9.81K ﹤0.01% 1285
2021
Q3 		$10K Sell
195
-381
-66% -$22.6K ﹤0.01% 1588
2021
Q2 		$40K Buy
576
+476
+476% +$36.3K 0.01% 923
2021
Q1 		$8K Buy
100
+57
+133% +$5.25K ﹤0.01% 1600
2020
Q4 		$4K Sell
43
-5
-10% -$611 ﹤0.01% 1745
2020
Q3 		$7K Sell
48
-53
-52% -$8.84K ﹤0.01% 1378
2020
Q2 		$20K Buy
101
+11
+12% +$2.28K ﹤0.01% 1052
2020
Q1 		$17K Buy
90
+15
+20% +$3.23K ﹤0.01% 1319
2019
Q4 		$15K Buy
+75
New +$13.9K ﹤0.01% 1780

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Quadrant Capital Group's LKFT Position: Q1 2026 in Review

Quadrant Capital Group increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 3.8% in Q1 2026, buying an estimated $4.4K and bringing the position to 3,653 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #1458.

Quadrant Capital Group first reported a position in LKFT in Q4 2019 and has held it in 25 quarters since. The position peaked at $324K in Q3 2024. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Quadrant Capital Group held 3,653 shares of Lakefront Biotherapeutics American Depositary Shares worth $110K as of Q1 2026.
  • Quadrant Capital Group bought 133 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $4.4K.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #1458 holding.
  • Quadrant Capital Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2019 and has held it in 25 quarters since.
  • Quadrant Capital Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $324K in Q3 2024.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.